Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...
2022
Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use
The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...
Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use
The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...
Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...
Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...
Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...
Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study
Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...
Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment
Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...
Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology...
Taibang Biologic Raises $300M in Post-Privatization Financing Round
Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021,...
Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies
Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing...
ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas
China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources...
Tus-Pharma to Acquire Sinotau Pharma for RMB 220 Million
China-based Tus-Pharmaceutical Group Co., Ltd (SHE: 000590) has announced plans to acquire 100% of Guangdong...
Eli Lilly Files for Baqsimi Approval in China to Treat Severe Hypoglycemia
Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...
Aosaikang’s ASKG315 Receives Ethics Approval for Phase I Cancer Trial in Australia
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced it has received ethical approval from Australia’s...
Ablaze Pharma to Invest $100M in Chengdu TRT R&D and Manufacturing Hub
Shanghai-based Ablaze Pharma announced plans to invest an initial $100 million in a new research...